您当前所在的位置:首页 > 产品中心 > 产品详细信息
1161233-85-7 分子结构
点击图片或这里关闭

2-{2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl}-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one

ChemBase编号:72512
分子式:C17H16F3N3O5S
平均质量:431.3862496
单一同位素质量:431.07627629
SMILES和InChIs

SMILES:
c1(cc(c2c(c1)c(=O)nc(s2)N1CCC2(CC1)OCC(O2)C)[N+](=O)[O-])C(F)(F)F
Canonical SMILES:
CC1COC2(O1)CCN(CC2)c1nc(=O)c2c(s1)c(cc(c2)C(F)(F)F)[N+](=O)[O-]
InChI:
InChI=1S/C17H16F3N3O5S/c1-9-8-27-16(28-9)2-4-22(5-3-16)15-21-14(24)11-6-10(17(18,19)20)7-12(23(25)26)13(11)29-15/h6-7,9H,2-5,8H2,1H3
InChIKey:
GTUIRORNXIOHQR-UHFFFAOYSA-N

引用这个纪录

CBID:72512 http://www.chembase.cn/molecule-72512.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
2-{2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl}-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one
IUPAC传统名
2-{2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl}-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one
别名
BTZ038
BTZ044
BTZ043 racemate
CAS号
1161233-85-7
PubChem SID
162037437
PubChem CID
49769085

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
Selleck Chemicals
S1097 external link 加入购物车 请登录
数据来源 数据ID
PubChem 49769085 external link

理论计算性质

理论计算性质

JChem
质子受体 质子供体
LogD (pH = 5.5) 3.6465611  LogD (pH = 7.4) 3.6465611 
Log P 3.6465611  摩尔折射率 98.1523 cm3
极化性 36.224674 Å3 极化表面积 96.95 Å2
可自由旋转的化学键 里宾斯基五规则 true 

分子性质

分子性质

安全信息 产品相关信息 生物活性(PubChem)
保存条件
-20°C expand 查看数据来源
成盐信息
racemate expand 查看数据来源

详细说明

详细说明

Selleck Chemicals Selleck Chemicals
Selleck Chemicals -  S1097 external link
Research Area
Description Infection
Biological Activity
Description BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2’-epimerase inhibitor acting as a new antimycobacterial agent that kill Mycobacterium tuberculosis.
Targets Decaprenylphosphoryl-β-D-ribose 2’-epim
IC50
In Vitro By targeting decaprenylphosphoryl-β-D-ribose 2’-epimerase, BTZ043 abolishes the formation of decaprenylphosphoryl arabinose, leading to cell lysis and death of Mycobacterium tuberculosis. BTZ043 displays similar activity against all clinical isolates of M. tuberculosis, including multidrug-resistant and extensively drug-resistant strains. BTZ043 displays significant activity against M. tuberculosis H37Rv and Mycobacterium smegmatis with MIC of 1 ng/mL (2.3 nM) and 4 ng/mL (9.2 nM), respectively, which is more potent than those of the existing tuberculosis (TB) drugs isoniazid (INH) and ethambutol (EMB) with MIC of 0.02-0.2 μg/mL and 1-5 μg/mL, respectively. BTZ043 is less effective in two different model systems (auxotrophy and starvation) involving metabolically inert M. tuberculosis, indicating that BTZ043 blocks a step in active metabolism similar to isoniazid (INH). BTZ043 treatment in M. smegmatis cells decreases the growth rate rapidly followed by a swelling of the poles and lysis of the cells after a few hours, which is similar but delayed in M. tuberculosis. [1] BTZ043 (1/4 MIC 0.375 ng/mL) in combination with TMC207 (1/4 MIC 20 ng/mL) has a stronger cidal effect on M. tuberculosis but not BTZ-resistant M. tuberculosis mutant than TMC207 alone at a concentration of 80 ng/mL. [2]
In Vivo In a mouse model of chronic tuberculosis, administration of BTZ043 at 37.5 mg/kg or 300 mg/kg for 4 weeks reduces the bacterial burden in the lungs and spleens by 1 and 2 logs, respectively. [1]
Clinical Trials
Features More active than EMB against M. tuberculosis.
Protocol
Animal Study [1]
Animal Models BALB/c mice infected with a low bacillary load (~200 CFU) of M. tuberculosis H37Rv via aerosol
Formulation Formulated in carboxymethyl cellulose formulation (0.25%)
Doses 37.5 mg/kg, or 300 mg/kg
Administration Oral gavage once daily
References
[1] Makarov V, et al. Science, 2009, 324(5928), 801-804.
[2] Lechartier B, et al. Antimicrob Agents Chemother, 2012.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle